Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2026-04-14 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
2025年年度报告业绩说明会预告公告
Investor Presentation Classification · 82% confidence The document is an announcement of a scheduled 2025 annual report performance briefing (业绩说明会) for investors, including timing, location, participants, and how to join. It is not the annual report itself, nor is it a simple release of financial highlights; rather, it organizes an investor presentation to explain the annual report and facilitate Q&A. This aligns best with the “Investor Presentation” category.
2026-04-14 Chinese
2025环境、社会及公司治理（ESG）报告
Environmental & Social Information Classification · 95% confidence The document is a comprehensive sustainability report (“可持续发展相关报告”) covering the company’s Environmental, Social, and Governance (ESG) performance in detailed chapters such as sustainable development management, governance structure, risk management, environment management, social responsibility, and key performance indicators based on GRI standards. It is not an earnings release, financial annual report, certification, or simple notice but a full ESG/CSR disclosure. This matches the definition for Environmental & Social Information (Code: SR).
2026-04-09 Chinese
会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (audit firm) for the fiscal year 2025. It details the auditor's qualifications, appointment process, audit procedures, and the company's assessment of the auditor's performance. It references the audit of the 2025 annual financial report and internal controls but does not contain the full annual report or the audit report itself. The document is relatively short (1552 characters) and serves as an announcement or evaluation related to the audit firm’s performance rather than the audit report or annual report itself. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and evaluations of audit firms' performance, excluding full annual reports. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-09 Chinese
2026年度董事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the remuneration scheme for directors and senior management for the year 2026. It details the salary standards, approval procedures, and related governance matters. It does not contain financial statements or performance data, nor is it a report or presentation. It is specifically about remuneration information for top executives and directors, which fits the definition of Remuneration Information (DEF 14A). The document length is short and focused solely on compensation details, confirming it is not an annual report or other financial filing.
2026-04-09 Chinese
申万宏源证券承销保荐有限责任公司关于北京三元基因药业股份有限公司2025年度募集资金存放、管理与实际使用情况的专项核查报告
Regulatory Filings Classification · 80% confidence The document is a "专项核查报告" (special inspection report) by the sponsor on the 2025 annual use, storage, and management of proceeds from a public offering, as required under Beijing Stock Exchange listing rules. It contains detailed fund usage tables, compliance statements, and attestation opinions by an accounting firm and the sponsor. It is not an earnings release, quarterly report, or annual report, nor a mere announcement of a report publication. Rather, it is a compliance filing under listing regulations that does not match any other specialized category, making it a general regulatory/compliance document.
2026-04-09 Chinese
关于拟修订《公司章程》公告
Governance Information Classification · 95% confidence The document is an announcement regarding proposed amendments to the company's Articles of Association (公司章程). It details the reasons for the amendments, specific changes to the articles, and mentions that the amendments will be submitted to the shareholders' meeting for approval. There is no financial data, no report attached or referenced as published, and no indication of a full report or regulatory filing. The content is about governance structure and company internal rules, specifically the company's charter. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2026-04-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.